“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diagnostics of the Future event.

”Vi uppmanar regeringen till krafttag”

DEBATT: Minskade satsningar på innovation inom life science riskerar Sveriges konkurrenskraft och folkhälsan. Det skriver företrädare för det strategiska innovationsprogrammet Swelife.

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, Head of Unit at the Swedish Medical Products Agency, who continues to persistently spread her message: don’t postpone the transition.

Myndighet varnar för att skjuta upp övergången till IVDR

Ursäkterna börjar ta slut för aktörer som ännu inte inlett anpassningen till kraven i EU:s nya regelverk IVDR. Det menar Helena Dzojic, enhetschef på Läkemedelsverket, som ihärdigt fortsätter att sprida sitt budskap: vänta inte med övergången.

The Swedish Research Council gets go-ahead for more long-term funding

Following a government decision, the Swedish Research Council will soon be able to approve ten-year grant periods for funding research infrastructure, which may affect the giant Max IV project, among others.

Byggstart för svenska innovationsklustret – fördubblar sin yta

Nu tas första spadtaget för Goco Active Lab, ett nytt nationellt center som ska stärka svensk life science.

The International Vaccine Institute’s office in Sweden is expanding

The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched, says Anh Wartel, Head of the office.

Internationella vaccininstitutets kontor i Sverige växer

Internationella vaccininstitutets kontor i Stockholm har nu funnits i över ett år. Under året som gått har utbildningar och projekt dragits i gång, berättar Anh Wartel, chef för kontoret.

700 personer varslas i Region Sörmland

Region Sörmland ska minska sina kostnader med en halv miljard kronor under nästa år och har anmält ett varsel för 700 medarbetare. Regionens läkemedelscentrum är en av de verksamheter där antalet anställda kan minska.

“Unfortunately, we are not strong when it comes to conducting clinical trials”

The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that aimed to find answers and solutions to this downward trend. One of the proposals was a stable

Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?

In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.

Getinge stärker närvaron på läkemedelsområdet i miljardaffär

Getinge förvärvar amerikanska High Purity New England, som tillverkar engångsprodukter för bioprocesser. Den svenska medtech-jätten betalar närmare 1,3 miljarder direkt, men affären kan växa till att kliva över tremiljarderstrecket.

This is the future location of the new national innovation cluster

Mölndal and Goco Health Innovation City will be the site of a new national innovation cluster for advanced therapies. The business community and the Swedish government are splitting the costs of the project, which is expected to produce new treatments for common diseases such as cancer and diabetes.

Norwegian company wins bidding battle for Sensidose

The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and leaving the way open for Norwegian company Navamedic.

The first Lyme disease vaccine faces a delay

Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the United States, which have forced the companies to drop half of the participants in an ongoing Phase III study.

Borreliavaccin försenas efter strul med studie

Pfizers och Valnevas borreliavaccin, som kan bli det första i sitt slag, försenas med åtminstone ett år. Orsaken är problem vid prövningssajter i USA som tvingat bolagen att stryka hälften av deltagarna i en pågående fas III-studie.

Uncertainty about the government’s life science work

The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now questions are being raised both about the government’s plans for the office and the Swedish life science strategy.

He got inside the head of Sweden’s vaccine hunter

The hunt for the COVID-19 vaccine is the theme of the new book Vaccinjägaren (The Vaccine Hunter). It tells the story of Richard Bergström’s mission as Sweden’s national vaccine coordinator and the scheming that went on behind the scenes in Europe. Author and medical journalist Nils Bergeå co-wrote the book with Richard Bergström.

Kristdemokraterna rekryterar från Sanofi

Jonas Sareld, Public Affairs Manager vid Sanofi, blir kanslichef för Kristdemokraterna i Region Stockholm.

Individual DNA passport could result in fewer drug side effects

You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer side effects if the drug treatment is adapted to their genes.

Novavax is developing a vaccine candidate against Covid-19 and seasonal flu

A combined vaccine against both Covid-19 and seasonal flu is showing promising results in studies, according to the American drug developer Novavax. The adjuvant, which forms an essential part of the vaccine, originates from Sweden.

Corline Biomedical tecknar avtal med Smerud för fas II-studie

No demand for new Covid vaccine – “It will probably be discarded”

So far, just under 6 000 doses of the Covid vaccine from Novavax have been used in Sweden, leaving over 1.4 million doses in stock. “They will probably be discarded due to lack of demand in Sweden as well as globally,” says Sweden’s National Vaccine Coordinator Richard Bergström to Life Science Sweden.

Tougher competition as the Novo Nordisk Foundation broadens its programme

Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, which has recently broadened its programme for leading innovators in medical research to apply to the entire Nordic region.